Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.89, for a total transaction of $928,950.00. Following the transaction, the chief executive officer now directly owns 575,661 shares in the company, valued at $9,722,914.29. The trade was a 8.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Saurabh Saha also recently made the following trade(s):

• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total transaction of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.53, for a total value of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total transaction of $2,891,000.00.

Centessa Pharmaceuticals Trading Down 6.3 %

Centessa Pharmaceuticals stock opened at $17.04 on Friday. Centessa Pharmaceuticals plc has a 52 week low of $5.58 and a 52 week high of $18.74. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm has a market capitalization of $1.93 billion, a PE ratio of -11.14 and a beta of 1.47. The business’s 50-day simple moving average is $16.09 and its 200-day simple moving average is $12.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of CNTA. Price T Rowe Associates Inc. MD lifted its holdings in shares of Centessa Pharmaceuticals by 16.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after acquiring an additional 418,615 shares during the period. Nantahala Capital Management LLC acquired a new position in shares of Centessa Pharmaceuticals during the second quarter valued at $4,064,000. Driehaus Capital Management LLC boosted its stake in shares of Centessa Pharmaceuticals by 89.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after purchasing an additional 987,997 shares during the last quarter. GSA Capital Partners LLP boosted its stake in Centessa Pharmaceuticals by 66.1% in the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock valued at $1,498,000 after acquiring an additional 37,275 shares during the last quarter. Finally, First Light Asset Management LLC boosted its position in shares of Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after purchasing an additional 1,778,515 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CNTA. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Oppenheimer reissued an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Jefferies Financial Group increased their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.